News

Otis Worldwide Corporation's Impressive Third Quarter Performance

Otis Worldwide Corporation's Impressive Third Quarter Performance

Otis Worldwide Corporation Reports Strong Third Quarter Growth

Otis achieves notable Service sales growth while enhancing its EPS outlook for the year

In the third quarter of 2025, Otis Worldwide Corporation (NYSE: OTIS) reported impressive financial metrics, including a 4% increase in net sales, reaching $3.7 billion. Organic sales improved by 2%, driven principally by Service net sales, which rose by 9% with organic growth at 6%. Overall, the results show a robust Service operating profit margin expansion of 70 basis points.

Quarterly Highlights

Key achievements during the third quarter include:

  • Net sales rose by 4%, organic sales increased by 2% from the previous year.
  • Service operating profit margin experienced a 70 basis points increase.
  • GAAP EPS declined by 29% at $0.95, while adjusted EPS rose by 9% to $1.05.
  • Maintenance portfolio units grew by 4%.
  • Modernization orders surged by 27% at constant currency, and backlog increased by 22%.
  • New Equipment orders were up by 4% at constant currency, and 7% excluding China.

Year-to-Date Performance

For the year-to-date period in 2025:

  • Service net sales increased by 6% with organic sales growth at 5%.
  • Boost in Service operating profit margin of 40 basis points.
  • GAAP EPS down by 21%. Nonetheless, adjusted EPS rose by 4%.
  • Operating cash flow was reported at $779 million, with adjusted free cash flow at $766 million.
  • Share repurchases amounted to approximately $800 million.

Leadership Insights

Judy Marks, Chair, CEO, and President of Otis, commented on the results: "Otis is back on a growth trajectory, thanks to our strong operational performance. Our Service strategy has seeded our highest organic sales growth and profit margin expansion of the year. Notably, our modernization orders have shown significant growth, evidencing a strong demand in the market. We are optimistic about the continued recovery in our New Equipment sector and accordingly, we have adjusted our EPS outlook upwards."

Future Outlook

Looking ahead, Otis is modifying its mid-point EPS outlook for 2025:

  • Anticipated net sales will range between $14.5 to $14.6 billion, representing roughly a 2% increase.
  • Organic sales are expected to grow approximately by 1%, with New Equipment sales forecasted to decline around 7% and Service sales projected to rise by 5%.
  • Adjusted operating profit is forecasted between $2.4 to $2.5 billion, inclusive of anticipated currency impacts.
  • The adjusted EPS guidance is between $4.04 to $4.08, reflecting a growth of 5 to 7%, with a projected effective tax rate around 24.8%.
  • Free cash flow is expected to be around $1.45 billion.

Otis continues to actively implement its UpLift program, which aims at achieving run-rate savings of approximately $200 million. Furthermore, Otis anticipates adding $40 million in savings from its transformation strategies in China by the end of 2025.

About Otis Worldwide Corporation

Otis is recognized globally as a leading manufacturer, installer, and service provider of elevators and escalators. The company moves 2.4 billion people daily and maintains approximately 2.4 million units in its Service portfolio, the largest in the industry. With a strong workforce of 72,000, including 44,000 field professionals, Otis is dedicated to enhancing the mobility experiences of customers and passengers across more than 200 countries.

Frequently Asked Questions

What were the key financial metrics Otis reported for Q3 2025?

Otis reported net sales of $3.7 billion, a 4% increase, with adjusted EPS rising by 9% to $1.05.

What contributed to the growth in Service sales?

The growth in Service sales was primarily driven by a robust performance in maintenance and modernization orders.

How does Otis plan to enhance its EPS outlook?

Otis is adjusting its EPS outlook based on strong operational performance and expected recovery in New Equipment sales.

What is Otis's forecast for 2025?

Otis anticipates net sales between $14.5 to $14.6 billion, with an adjusted EPS between $4.04 to $4.08.

What is the UpLift program?

The UpLift program is an initiative by Otis aimed at transforming operations to increase efficiency and achieve significant savings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 37

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 40

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 52

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 28

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 46

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 63

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 35

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading

Top 5 Most Recently Viewed Articles

NORBIT Secures Significant NOK 120M Defence Order

Updated Category News Views 288

NORBIT Secures Significant NOK 120 Million Defence Order NORBIT has recently made an exciting announcement regarding a significant contract within its segment PIR. The company has been awarded a manufacturing order valued at NOK 120 million from a European client specializing in defence and security. This order is poised for delivery in late 2025 and early 2026, marking a...

Continue Reading
Shareholder Concerns Over BCO, SEM, NATL Transactions

Updated Category News Views 12

Is There Smoke Without Fire in Recent Company Mergers? Well, here we go again. It seems every time deals like these pop up, questions start flying about fairness and insider scoops. The big fish here? The Brink's Company (NYSE:BCO), Select Medical Holdings Corporation (NYSE:SEM), and NCR Atleos Corporation (NYSE:NATL). Halper Sadeh LLC, the investor rights firm, is on a...

Continue Reading
TG Therapeutics Director’s Recent Stock Sale Raises Questions

Updated Category News Views 120

Significant Insider Transaction at TG Therapeutics Recently, an important transaction came to light involving Yann Echelard, Director at TG Therapeutics (NASDAQ:TGTX). The details were revealed through the latest SEC filing. On a given date, Echelard sold 5,000 shares, raising a total of $162,850. Such insider trading can often prompt discussions regarding the company’s...

Continue Reading
Innovative Leadership in Facilities Management Revolutionized

Updated Category News Views 214

MasonMade Ventures Launches to Revamp Facilities Management Serial Entrepreneurs Aim to Disrupt the FM Industry through Innovative Software Solutions and Expert Trades MasonMade Ventures, established by visionary entrepreneurs Joseph Scaretta and Moses Carrasco, is set to change the face of facilities management. This operational holding company focuses on investing in...

Continue Reading
Kyverna Therapeutics Engages Investors at Upcoming Events

Updated Category News Views 136

Kyverna Therapeutics' Upcoming Investor Conferences Kyverna Therapeutics, Inc. (NASDAQ: KYTX), a pioneering clinical-stage biopharmaceutical company committed to innovative cell therapies for autoimmune diseases, is slated to present at a series of significant investor conferences this September. Warner Biddle, the Chief Executive Officer of Kyverna, will be the...

Continue Reading